Eris Lifesciences Ltd. share price target

Eris Lifesciences' (ERIS) Q1FY26 EBITDA was broadly in line with our estimate (Rs2.75bn; up 11% YoY). Though Q1FY26 revenue growth (up 7.4% YoY) was muted, we see pick up in coming quarters as insulin shortages stabilize, export pick up and likely additional market share gain from human insulin market. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to scale up from the current level of 35% in FY25 as revenue scales up from recent...

Strong FY26 guidance with +15% revenue growth with 36% OPM. up 70% YoY). Eris has opted for inorganic route to diversify and scale up expect margins to scale up from the current level of 35% as revenue scales up from recent acquisitions, which are currently operating at sub-optimal profitability. The company has multiple growth levers such as broad-based...

Eris Lifesciences (ERIS) posted lower-than-expected 4QFY25 performance. This has been largely due to a marginal slip in the execution, particularly in the insulin revenue.

Base domestic growth at 12% vs IMP growth of 8% due to new product launches and price increase

Eris Lifescience’s (ERIS) 3QFY25 performance came in below our estimates. Lower-than-expected revenue growth led to lower operating leverage, which affected the overall performance.

Q2 revenue/PAT above our estimates due to better traction in both base and acquired businesses

ERIS posted strong revenue performance in Q4 with a beat of 8%, but EBITDA came below BBG consensus due to higher opex and one-offs

Harnessing Growth Through Strategic Acquisitions

Q1 revenue/PAT in line but operating margin ahead of consensus at 36.4% (+395bps YoY)

Consolidated Q4 revenue/EBITDA growth of 32%/23% YoY missed consensus by 3%/10%